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Exposure to more than one toxic compound is common in real life. The resulting toxic effects are often more than the simple sum of the effects of
the individual compounds. It is unlikely that it will ever be possible to test all combinations. It is therefore highly desirable to improve or develop
means for reasonably approximating predictions of interactions. In order to be valid and extrapolatable, these predictions are most promising if they
are mechanism-based. Examples will be given for possibilities of mechanism-based predictions of interactions which exceed trivialities of simple
increases by enzyme induction of enzymatic rates of a given biotransformation pathway leading to a toxic metabolite. Instead, examples will be pro-
vided where competition between various enzymes for shunting the same substrate into divergent pathways can lead to predictable dramatic
changes in toxicity by shifting the metabolic routes under conditions of no significant changes of overall metabolism. Further examples are given on
predictable interactions between chemicals which need bioactivation for exerting their toxicity and chemicals which effect hormonal status and
other endogenous factors which in turn modify enzymes involved in the control of toxic metabolites.-Environ Health Perspect 102
(Suppl 9):5-9 (1994)
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Introduction
Interactions between xenobiotics based on
enzyme inhibition can be very profound.
Figure 1 shows an example ofinhibition of
the major microsomal epoxide hydrolase
mEHb* at low concentration (0.3 pM) of
1,1,1-trichloropropene 2,3-oxide (2). At
this concentration, no influences are
known on any other enzyme contributing
to the control ofepoxides by either form-
ing them or metabolizing them further. In
the absence of this, modulator phenan-
threne does not induce mutations in
Salmonella typhimurium TA1537 to a mea-
surable extent in agreement with the
known noncarcinogenicity of the com-
pound. However, 0.3 ,uM trichloropropene
oxide leads to a pronounced mutagenicity.
This concentration ofthe modulator led to
an inhibition ofmEHb (measured with the
standard substrate benzo[a]pyrene 4,5-
oxide which has a similar affinity to the
enzyme as phenanthrene 9,10-oxide) of
approximately 95%, that is to a lowering of
*mEH : The major microsomal epoxide hydrolase pos-
sessing a broad substrate specificity diagnostically
including benzo[alpyrene 4.5-oxide (1).
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gen by sufficiently raising the steady state
concentration ofthe responsible epoxide.
Interactions betweenXenobiotics
Based onEnzymeInduction
The well known mutagenic carcinogen
benzo[a]pyrene is virtually nonmutagenic
when activated by liver microsomes from
rats which had not been pretreated with
the effective mEHb activity by a factor of
roughly 20. Phylogenetic investigations
had shown that the mEHb activities varied
between individual vertebrate species by up
to about 1000-fold (3). Thus, modulations
by inhibitors far lower than variations in
mEHb activities occurring between verte-
brate species were sufficient to convert an
apparent nonmutagen to a clearcut muta-
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Figure 1. Dose dependency of the mutagenic effect of phenanthrene after activation with liver microsomes from
mice induced with Aroclor 1254 (500 mg/kg) for Salmonella typhimuriumTAl537. o, incubation without addition of
an inhibitorfor epoxide hyratase. *, 0,6 pl 1,1,1-trichloropropene 2,3-oxide in 10 pl dimethylsulfoxide was added to
the incubation mixture. The horizontal lines indicate the range of numbers of colonies on plates without test com-
pound (n = 8). Data from Buecker et al. (2); reproduced by permission of Mutation Research.
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Figure 2. Activation of benzo[aJpyrene to a mutagen: potentiation by selective induction of monooxygenase.
Benzo[alpyrene and Salmonella typhimurium TAl537 bacteria were incubated with hepatic microsomes from con-
trol male Sprague-Dawley rats or from rats that had been pretreated intraperitoneally with 10 mg/kg of
3-methylcholanthrene in sunflower oil and killed 3 days later. Data from Oesch and Glatt (4); reproduced by per-
mission of IARC publications.
enzyme inducers (4). However, high muta-
genicity is observed after induction by
3-methylcholanthrene. The dramatic differ-
ence is shown in Figure 2. The special prac-
tical importance is that in some cases such
enzyme inductions may be a prerequisite for
the mutagenicity and carcinogenicity to
occur. This may be through induction by a
compound different from the compound in
question (interaction) or by a dose of the
compound which is sufficient for induction
(potential threshold ofgenotoxicity and car-
cinogenicity due to induction of constitu-
tively not induced enzymes).
Interacdons betweenXenobiotics
Based onShifts ofRoutesof
Metabolism
We incubated [14C]-benzo[a]pyrene with
control and with trans-stilbene oxide
(TSO)-induced rat liver microsomes and
the metabolites were separated by HPLC
(Table 1). Standard compounds and two
different elution systems were used to char-
acterize the metabolites. The results pre-
sented are derived from a separation using
an acetonitrile-water gradient. Similar
results were obtained using a methanol-
water gradient with the exception that sep-
aration of the 4,5-epoxide peak from the
3,5-quinone peak was achieved with the
acetonitrile-water but not with the
methanol-water gradient. In addition, it
was confirmed that metabolites,which were
tentatively identified by their mobilities as
dihydrodiols, were markedly reduced or
disappeared when the inhibitor of mEHb,
1,1,1-trichloropropene 2,3-oxide was pre-
sent. As seen from Table 1, the total quan-
tities of the metabolites was not
significantly changed after TSO-treatment
of the rats. However, a most remarkable
shift of the metabolism occurred. The
quantity of metabolites which were
oxidized at the benzo ring (7,8-dihydroxy-
7,8-dihydrobenzo[a]pyrene, 9,10-dihy-
droxy-9, 1 0-dihydrobenzo [a]pyrene,
9-hydroxybenzo[a]pyrene) was greatly
diminished, while far more K-region
metabolites (4,5-dihydroxy-4,5-dihy-
drobenzo[a]pyrene, benzo[a]pyrene 4,5-
oxide) were formed. The ratio between
7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene
and 4,5-dihydroxy-4,5-dihydrobenzo [a]-
pyrene was more than 20 times lower with
TSO-induced microsomes than with con-
trol microsomes. Only insignificant
changes were observed in the peaks
containing the quinones and 3-hydroxy-
benzo[a]pyrene. As expected from the
induction of mEHb by TSO, a much
higher percentage ofthe metabolically pro-
Table 1. Effect of trans-stilbene oxide administration on the pattern of benzo[a]pyrene metabolism by rat livermicrosomes.a
Radioactivity with Control rats Trans-stilbene oxide treated rats
mobility ofthefollowing pmoles, pmoles, RatiobTSO-
reference compounds mg protein x 20 min % of metabolites mg protein x 20 min % of metabolites treated/control
9,10-Dihydroxy-9,10- 1240 ± 90 13.5 460 ± 10 4.3 0.37
dihydrobenzo[a]pyrene
4,5-Dihydroxy-4,5- 430 + 10 4.7 2670 ± 250 25.0 6.21
dihydrobenzo[alpyrene
7,8-Dihydroxy-7,8- 330± 10 3.6 90± 30 0.8 0.27
dihydrobenzo[a]pyrene
Benzo[a]pyrene 1,6- 3690 ± 20 40.2 3750± 480 35.0 1.01
quinone and 3,6-quinone
Benzo[a]pyrene 4,5-oxide 430 ± 90 4.7 760 ± 70 7.1 1.76
9-Hydroxybenzo[a]pyrene 320 ± 10 3.5 120 ± 10 1.1 0.37
3-Hydroxybenzo[a]pyrene 2190 ± 170 23.9 1840 ± 320 17.2 0.84
Others 550 ± 40 5.9 1030± 80 9.5 1.87
Total 9180 ±390 100.0 10700±1250 100.0 1.16
aData from Buecker et al. (5); reproduced by permission of Molecular Pharmacology. bRatio of metabolites present after 20 min incubation with microsomes from trans-stil-
bene oxide treated and control rats.
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duced benzo[a]pyrene 4,5-oxide was con-
verted to the corresponding dihydrodiol
with TSO-induced microsomes.
Various doses of benzo[a]pyrene were
activated by microsomes or postmitochon-
drial fractions to mutagens which were
detected by the reversion ofvarious his-
Salmonella typhimurium strains. In general,
induction by TSO, markedly decreased the
mutagenicity of benzo[a]-pyrene. The
greatest reduction (by more than 90%) was
obtained when post-mitochondrial frac-
tions and the strain TA100 were used
(Figure 3A). Using microsomes, TSO-
treatment reduced the mutagenicity with
TA100 by 65% (Figure 3B) and with
TA98 by 40% (Figure 3C, round sym-
bols). However, TSO treatment only
slightly reduced the mutagenicity with
TA1537 (Figure 3D, round symbols). The
differences can be easily explained. The
Salmonella assay is a backward mutation
assay which requires specific mutations to
reconstruct a functional his gene. Different
his- strains vary in their susceptibility to
reversion by different benzo[a]pyrene
metabolites. TAI00 and TA98 are easily
reverted by benzo[a]pyrene 7,8-dihydrodiol
9,10-oxides, and by benzo[a]pyrene 4,5-
oxide. The strain TA1537 is less sensitive
towards the 7,8-dihydrodiol 9,10-oxides
but is highly sensitive to the 4,5-oxide (6).
The greater decrease of mutagenicity by
TSO induction with the strains which are
sensitive to 7,8-dihydrodiol 9,10-oxides
(TAIOO, TA98) when compared with a
strain which is relatively insensitive towards
these dihydrodiol epoxides (TA1537), sug-
gests that the reduction ofthe mutagenicity
is caused to a significant extent, by the
decreased oxidation ofbenzo[a]pyrene at
the benzo ring. The decreased benzo ring
metabolism is accompanied by increased
K-region metabolism, leading to the muta-
genic benzo[a]pyrene 4,5-oxide, but
mEHb, which is induced by TSO (7), can
inactivate this mutagen (4,8).
The mEHb inhibitor 1,1,1-trichloro-
propene oxide (9) potentiated the muta-
genic effects both with control and with
TSO-induced microsomes (Figure 3C,3D).
This experiment could be performed only
with TA98 and TA1537 since 1,1,1-
trichloropropene oxide is too mutagenic
with TA100 (10). With TA98, inhibition
of mEHb increased the mutagenicity of
benzo[a]pyrene activated with control
microsomes about 3-fold, and with TSO-
induced microsomes about 5-fold (Figure
3C). Also, with TA1537, inhibition of
mEHb potentiated the mutagenicity more
strongly when TSO-induced microsomes
were used for the activation (Figure 3D).
This shows the increased importance of
mEHb for the inactivation of mutagenic
benzo[a]pyrene metabolites after a shift of
the metabolism to the K-region, since the
K-region epoxide benzo[a]pyrene 5,6-oxide
is an excellent substrate ofmEHb, indeed is
used as its diagnostic substrate (1).
Thus, shifts in routes ofmetabolism due
to interactions between xenobiotics can
profoundly change their biological effects.
Interacdons betweenXenobiotics
Basedon Posttranslational
Modifications ofEnzyme Proteins
Overall organismic activities ofxenobiotic-
metabolizing enzymes may change by alter-
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ing enzyme amount or specific activity by
induction, repression, activation, or inhibi-
tion. Very widely studied is the contribu-
tion ofinduction, which is a relatively slow
process requiring the biosynthesis of the
enzyme protein. The possibility ofa faster
regulation of xenobiotic metabolism by
posttranslational modification (e.g., by
phosphorylation) ofan already preexisting
protein has only recently received atten-
tion. A central role in the metabolism of
xenobiotics is played by the cytochrome
P450-dependent monooxygenases.
Purified cAMP-dependent protein
kinase (PKA) and purified calcium/phos-
pholipid-dependent protein kinase (PKC)
catalyze, donor- and acceptor-selectively,
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Figure 3. Effect of trans-stilbene oxide treatement on the activation of benzo[alpyrene to mutagens. Male
Sprague-Dawley rats (210-230 g) received intraperitoneal injection of trans-stilbene oxide (2 mmole/kg body
weight, dissolved in 0.5 ml sunflower oil) or sunflower oil only 72, 48, and 24 hr before sacrifice. Various amounts
of benzo[alpyrene, 9000g supernatant fraction (A) or microsomes (BD) of liver homogenate, a NADPH generating
system and his- Salmonella typhimurium (A,B: TAl00; C: TA98; D: TAl537) were mixed with histidine-poor soft
agar and poured on a minimal agar plate. In part ofthe experiments, 1 mmole ofthe mEHb inhibitor 1,1,1-trichloro-
propene 2,3-oxide (9) was added. Colonies (his' revertants) were counted after an incubation for 2 days at 37°C.
The values represent means ± SD of three experiments with trans-stilbene oxide treated and of two experiments
with control animals. Livers from two animals were pooled and two plates were run for each experimental condi-
tion. The hatched zones show means ± SD of the number of revertant colonies in the absence of benzo[alpyrene.
o, control rats; *, trans-stilbene oxide-treated rats. o, control rats with mEHb inhibitor. *, trans-stilbene oxide-
treated rats, with mEHb inhibitor.A) S. typhimurium TA 100,9000g supernantant. B)S. typhimuriumTA 100, micro-
somes. C) Styphimurium TA 98, microsomes. D) S. typhimurium TA 1537, microsomes'. Data from Buecker et al.
(5); reproduced by permission of MolecularPharmacology.
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the phosphorylation of some, but not all,
purified cytochrome P450 isoenzymes,
while the phosvitin/casein type II kinase
was inactive for 13 cytochrome P450
isoenzymes investigated (11-14). In order
to see whether this process also occurred in
the intact cell, hepatocytes were exposed to
32P-orthophosphate to label the intracellu-
lar ATP pools. Hepatocytes were isolated
from the liver of adult male Sprague-
Dawley rats pretreated with phenobarbital
in order to induce the cytochrome P450
isoenzymes 2B1 and 2B2 (cytochromes
P450b and P450e, the two major pheno-
barbital-inducible cytochromes P450).
Among the 13 investigated isoenzymes,
these two had been the best substrates of
PKA in the cell free system (12). In the
absence ofstimulation, the incorporation
of radioactive phosphate into cytochromes
P450 (isolated and purified after the incu-
bation.with 32P-orthophosphate) was very
low. After stimulation by extracellular
glucagon or by membrane permeating
cAMP-derivatives (N6,02'-dibutyryl-
cAMP and 8-thiomethyl cAMP) a marked
incorporation of 32P-phosphate into
cytochrome P450 took place (15).
Autoradiography ofgel electrophoretically
separated proteins from solubilized micro-
somes of these hepatocytes and ofpurified
cytochromes P450 combined with visual-
ization on Western blots by specific anti-
bodies showed that four cytochromes P450
were phosphorylated, cytochromes P450
2B1 and2B2, and two cytochromes P450
2B1-related proteins, one of them
inducible by phenobarbital (15). Pyerin
and Taniguchi (16) and Koch and
Waxman (17) have also observed that the
major phenobarbital-inducible cytochrome
P450 is phosphorylated in the intact hepa-
tocytes and in the whole animal (17)
where phosphorylation took place in the
liver in the absence of any exogenous
stimulation and was increased by N6, 02'
-dibutyryl-cAMP and theophyllin. Johans-
son et al. (14) reported on the phospho-
rylation of the ethanol-inducible
cytochrome P450 isoenzyme 2E1 which
was stimulated by cAMP analogues.
The phosphorylation of cytochromes
P450 2B1 and 2B2 in-intact hepatocytes
led to a marked decrease in the microsomal
monooxygenase activity towards substrates
ofthese isoenzymes (18): The O-dealkyla-
tion of 7-pentoxyresorufin which repre-
sents a selective substrate ofcytochromes
P450 2B1 and 2B2 was markedly
decreased; similarly, the metabolism of
testosterone was markedly and regio- and
stereo-selectively changed in those posi-
tions of the steroid molecule which are
attacked by cytochromes P450 2B1 and
2B2. After treatment of the hepatocytes
with the agents leading to phosphorylation
ofcytochromes 2B1 and 2B2 (cAMP deriv-
atives), the 16p-hydroxylation of testos-
terone which is catalyzed by cytochromes
P450 2B1 and 2B2 was decreased about
50% (18). The influence ofthe phospho-
rylation on the hydroxylation at the 16oc-
position was "diluted" (decreased about
30%) by those isoenzymes which in addi-
tion to the phosphorylated cytochromes
P450 2B1 and 2B2 also catalyze this reac-
tion, namely cytochromes P450 2C7
(P450f, immunologically crossreactive with
cytochrome P450 2B1, constitutive isoen-
zyme), cytochrome P450 2C11 (P450h,
male specific testosterone 2oc/16oc-hydrox-
ylase) and cytochrome P450g (male
specific, strain-dependent) (19,20). Cyto-
chromes P450 2B1 and 2B2 also catalyze
the oxidation of the 175-OH group of
testosterone to a keto group (conversion to
androstenene-3,17-dione). However, this
reaction is still less specific. Hence, the
decrease in activity due to phosphorylation
was even more "diluted" at this position
and did not reach statistical significance.
Jansson et al. (21) reported that in a cell-
free system phosphorylation ofcytochrome
P450 LM2 (the major phenobarbital-
inducible cytochrome P450 in the rabbit
liver, P450 2B4), inhibited the interaction
of the latter with the former, leading to a
loss of the stimulatory activity of cyto-
chrome b5 prior to its reconstitution with
cytochrome b5. Taniguchi et al. (22)
reported that in a cell-free system the treat-
ment of cytochrome P450 purified from
the liver of a phenobarbital-treated rabbit
with purified PKA leads to a destruction of
cytochrome P450 to cytochrome P420.
Johansson et al. (14) reported that in hepa-
tocytes the agents which lead to an increase
of phosphorylation of cytochrome P450
2E1 (glucagon and cAMP analogues) also
lead to an increase in the degradation rate
ofcytochrome P450 2E1. Agents which
protected against the degradation also pro-
tected against phosphorylation. Based on
these observations, the authors suggested
that phosphorylation leads to a more rapid
degradation of cytochrome P450 2E1.
Thus, phosphorylation of cytochromes
P450 may influence metabolism by modu-
lating their activity as well as theirlevels.
The selective phosphorylation of
defined cytochromes P450 by some defined
protein kinases which themselves are under
differential control in intact cells (and to
the limited extent in which it has been
investigated, also in animals) followed by
highly selective and predictable changes in
metabolic rates strongly suggests that inter-
actions between xenobiotics may be
expected on this level. Some expected
interactions are listed in Figure 4. The issue
gains further significance by our recent
demonstration that these processes
also occur in human tissue (Oesch-
Bartlomowicz, Arens, Fahndrich, Vogel
and Oesch, manuscript in preparation).
Conclusions
Interactions between xenobiotics may pro-
foundly influence their toxic effects. The
permutations of possible interactions are
expected to lead to an infinite number of
conceivable situations which may never be
amenable to individual investigation.
Development ofpossibilities for reasonable
approximations and predictions are there-
fore desirable. They may be most effective
ifthe underlying considerations are mecha-
nism-based. This overview summarizes a
few possibilities such as enzyme inhibition,
enzyme induction, shift of routes ofmetab-
olism, and posttranslational modification
ofenzymes.
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Figure 4. Interactions to be expected
between compounds metabolized by
cytochromes P450 phosphorylated by protein
kinase A and compounds leading to
increases in cAMP.
1. P450 2B1 substrates: Several cytostatic
drugs (cyclophosphamide, ifosfamide),
many barbiturates, several anticonvul-
sants.
2. P450 2E1 substrates: Many
nitrosamines (dimethyl, diethyl,
methyl,propyl, methyl, benzyl), vinyl
halides, vinyl carbamate, urethan, acry-
lonitrile, styrene, benzene, many
haloalkanes, chlorozoxazone.
3. Stimulators of adenylate cyclase: b-
active sympathomimetics; endogenous
stimulators released upon cachetic sit-
uation (glucagon) or upon cardiac insuf-
ficiency (adrenalin or noradrenalin, or
both).
4. Compounds leading to decrease of
adenylate cyclase activity: ,B-blockers.
5. Phosphodiesterase inhibitors: methyl-
xanthines (theophylline, caffeine).
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